News » Transgender Individuals Likely Have Higher Risk for Heart Disease

Transgender Individuals Likely Have Higher Risk for Heart Disease

A review published by Michael S. Irwig, MD, examines the relationship between sex steroids and cardiovascular events

WASHINGTON (Aug. 3, 2018) — Transgender individuals may be at higher risk for myocardial infarction and death due to cardiovascular disease, according to several studies. This increased risk may be due to the hormone therapy that transgender patients take for masculinization or feminization.

A review authored by Michael S. Irwig, MD, associate professor of medicine at the George Washington University (GW) School of Medicine and Health Sciences and director of the Andrology Center at the GW Medical Faculty Associates, examined several studies that followed transgender individuals on hormone therapy.

“Many transgender patients take either testosterone or estrogen for masculinization or feminization,” explained Irwig. “Some studies have suggested that transgender people have an increased risk for heart attack and death due to cardiovascular disease.”

The review focuses on cardiovascular events (myocardial infarction, stroke and venous thromboembolism) and surrogate markers — including blood pressure and lipid concentrations — in transgender patients on hormone therapy who may or may not have undergone gender affirmation procedures. The studies that the review covers show that transgender women appear to have increased risk for cardiovascular events due to hormone therapy whereas the data is unclear for transgender men. It is well known that estrogen therapy for trans women increases their risk of blood clots (deep venous thromboses).

“In clinical studies that followed transgender patients, rates for myocardial infarction were consistently higher in transgender women on estrogen therapy than in transgender men on testosterone,” Irwig said. “The relationship between endogenous sex hormones and heart disease is complex. In cisgender women, estrogen may have a protective effect.”

Given that hormone therapy is often essential in the management of transgender patients, Irwig suggests that more research is needed on the effects and risk of hormone therapy in older transgender populations and on the safest forms of estrogen therapy.

The review, titled “Cardiovascular Health in Transgender People,” is published in Reviews in Endocrine and Metabolic Disorders.

Media: To interview Dr. Irwig, please contact Lisa Anderson at lisama2@gwu.edu or 202-994-3121.

###

About the GW School of Medicine and Health Sciences: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation’s capital and is the 11th oldest in the country. Working together in our nation’s capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. smhs.gwu.edu